Executive Vice President, Head of International
Hiring Company
About the Role
Greater San Francisco, CA Area (Hybrid - Headquarter location)
The Company is seeking an Executive Vice President, Head of International to lead its business outside the United States and drive international growth, commercial performance, launches, geographic expansion, and organizational development. The role oversees international business planning, P&L, resource allocation, forecasting, and performance management across established and developing markets. Responsibilities include building regional capabilities, leading launch readiness and market access, guiding pricing and reimbursement strategies, and managing distributors, licensing partners, and direct-market operations. The executive will also shape market-entry and investment decisions, develop a high-performing international leadership team, and collaborate across enterprise functions to align commercial plans with portfolio and patient needs. Candidates should have a bachelor’s degree; an advanced degree is preferred, along with at least 15 years of progressive pharmaceutical or biotechnology commercial leadership experience and substantial international responsibility. Required experience includes P&L ownership, multi-country leadership, and successful commercialization of rare disease, specialty-care, or other high-value, low-prevalence products. Candidates should bring expertise in international pricing, reimbursement, market access, launch sequencing, and geographic expansion, as well as experience with direct and partner-led operating models. Strong strategic, financial, and operational judgment, cross-cultural communication, negotiation, and the ability to build lean organizations and lead through change are essential.
Functions:
- Sales/Revenue
- Business Development
Est. Compensation
USD $150,000-$425,423 (total) per year
Estimated by Revelio Labs
About the Company
Innovative biopharmaceutical company
Industry
Pharmaceuticals
Type
Privately Held
Age
employees
201-500
Funding
>$200m